Emerging clinical evidence from the Phase III RELATIVITY-047 trial has established the role of dual checkpoint inhibition with PD-1 and LAG-3 blockade in advanced melanoma . The study highlights meaningful improvements in key clinical outcomes , including progression-free survival and objective response rates, compared to nivolumab monotherapy, while maintaining a manageable safety profile . To explore the study design, patient population, efficacy outcomes, and safety insights from RELATIVITY-047, Bristol Myers Squibb ® , India invites you to an exclusive session under the lecture series “ Reimagine Melanoma Care: Unlocking Novel IO pathway with LAG-3 & PD-1 Blockade .” Join expert Oncologist Dr.
Chandragouda Dodagoudar for Session 3 on “ Clinical Evidence for Dual Checkpoint Inhibition in Melanoma: RELATIVITY-047 ” on Saturday, 16th May 2026 , from 7:00 PM to 8:00 PM IST . Don’t…
